The U.S. Food and Drug Administration granted approval for the original Abbreviated New Drug Application (ANDA) 078442 covering Alprazolam extended‑release tablets on October 15, 2007. A subsequent labeling supplement (submission number 2) received approval on November 29, 2011.
The approved products are oral, extended‑release tablets marketed under the brand name Alprazolam. Four product numbers were listed: 001 (0.5 mg), 002 (1 mg), 003 (2 mg), and 004 (3 mg). Each contains alprazolam as the sole active ingredient.
All four tablet strengths are currently marked as discontinued. The sponsor for the application is PH Health, and none of the products are designated as reference drugs or reference standards.
Laissez votre note